JP2014534258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534258A5 JP2014534258A5 JP2014542952A JP2014542952A JP2014534258A5 JP 2014534258 A5 JP2014534258 A5 JP 2014534258A5 JP 2014542952 A JP2014542952 A JP 2014542952A JP 2014542952 A JP2014542952 A JP 2014542952A JP 2014534258 A5 JP2014534258 A5 JP 2014534258A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant protein
- growth factor
- full length
- neutralizing
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 28
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 28
- 239000003102 growth factor Substances 0.000 claims 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 230000003472 neutralizing effect Effects 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 230000002163 immunogen Effects 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 claims 4
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 claims 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 4
- 102000009016 Cholera Toxin Human genes 0.000 claims 3
- 108010049048 Cholera Toxin Proteins 0.000 claims 3
- 238000006386 neutralization reaction Methods 0.000 claims 3
- 102000004152 Bone morphogenetic protein 1 Human genes 0.000 claims 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 claims 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims 2
- 102400001368 Epidermal growth factor Human genes 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 2
- 229940116977 epidermal growth factor Drugs 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- -1 PDGF Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563128P | 2011-11-23 | 2011-11-23 | |
| US61/563,128 | 2011-11-23 | ||
| US201261654401P | 2012-06-01 | 2012-06-01 | |
| US61/654,401 | 2012-06-01 | ||
| PCT/IB2012/002876 WO2013076580A2 (en) | 2011-11-23 | 2012-11-21 | Recombinant proteins and their therapeutic uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064763A Division JP6570081B2 (ja) | 2011-11-23 | 2017-03-29 | 組換えタンパク質及びそれらの治療的用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534258A JP2014534258A (ja) | 2014-12-18 |
| JP2014534258A5 true JP2014534258A5 (enExample) | 2016-01-21 |
| JP6121436B2 JP6121436B2 (ja) | 2017-04-26 |
Family
ID=47716105
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542952A Active JP6121436B2 (ja) | 2011-11-23 | 2012-11-21 | 組換えタンパク質及びそれらの治療的用途 |
| JP2017064763A Expired - Fee Related JP6570081B2 (ja) | 2011-11-23 | 2017-03-29 | 組換えタンパク質及びそれらの治療的用途 |
| JP2019072235A Active JP6953467B2 (ja) | 2011-11-23 | 2019-04-04 | 組換えタンパク質及びそれらの治療的用途 |
| JP2021159307A Active JP7470669B2 (ja) | 2011-11-23 | 2021-09-29 | 組換えタンパク質及びそれらの治療的用途 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064763A Expired - Fee Related JP6570081B2 (ja) | 2011-11-23 | 2017-03-29 | 組換えタンパク質及びそれらの治療的用途 |
| JP2019072235A Active JP6953467B2 (ja) | 2011-11-23 | 2019-04-04 | 組換えタンパク質及びそれらの治療的用途 |
| JP2021159307A Active JP7470669B2 (ja) | 2011-11-23 | 2021-09-29 | 組換えタンパク質及びそれらの治療的用途 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US9902760B2 (enExample) |
| EP (2) | EP2782598B1 (enExample) |
| JP (4) | JP6121436B2 (enExample) |
| KR (2) | KR102274211B1 (enExample) |
| CN (3) | CN108864291A (enExample) |
| AU (3) | AU2012342117B2 (enExample) |
| BR (1) | BR112014012460B1 (enExample) |
| CA (1) | CA2856255C (enExample) |
| DK (1) | DK2782598T3 (enExample) |
| ES (1) | ES2812564T3 (enExample) |
| HR (1) | HRP20201282T1 (enExample) |
| HU (1) | HUE050438T2 (enExample) |
| IL (2) | IL232645B (enExample) |
| LT (1) | LT2782598T (enExample) |
| MX (2) | MX354902B (enExample) |
| MY (2) | MY188083A (enExample) |
| PL (1) | PL2782598T3 (enExample) |
| PT (1) | PT2782598T (enExample) |
| RS (1) | RS60782B1 (enExample) |
| RU (2) | RU2650574C2 (enExample) |
| SI (1) | SI2782598T1 (enExample) |
| WO (1) | WO2013076580A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013076580A2 (en) * | 2011-11-23 | 2013-05-30 | Bioven 3 Limited | Recombinant proteins and their therapeutic uses |
| US20160333087A1 (en) | 2015-05-12 | 2016-11-17 | Bioven 3 Limited | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
| US20190358320A1 (en) * | 2015-05-12 | 2019-11-28 | In3Bio Ltd. | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
| IL300235A (en) * | 2017-07-18 | 2023-03-01 | In3Bio Ltd | Synthetic proteins and their therapeutic uses |
| CN107880133A (zh) * | 2017-11-04 | 2018-04-06 | 海南大学 | 促皮质素与胰岛素样生长因子1融合蛋白及其制备方法 |
| WO2019179361A1 (zh) * | 2018-03-21 | 2019-09-26 | 傅惠芳 | 改善括约肌闭锁不全的组合物及其医药组成物与用途 |
| WO2020046982A1 (en) * | 2018-08-27 | 2020-03-05 | University Of Virginia Patent Foundation | Compositions and methods for preventing and treating virus infection |
| JP7631240B2 (ja) * | 2019-06-25 | 2025-02-18 | イン３バイオ・リミテッド | 安定化キメラ合成タンパク質及びその治療的使用 |
| CA3157334A1 (en) * | 2019-11-07 | 2021-05-14 | Miguel Angel MOLINA-VILLA | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors |
| CN112574309B (zh) * | 2019-12-05 | 2023-06-16 | 启愈生物技术(上海)有限公司 | 一种抗pd-l1纳米抗体及其用途 |
| US20230097992A1 (en) * | 2020-03-25 | 2023-03-30 | The Regents Of The University Of Colorado, A Body Corporate | Bivalent egf fusion toxins |
| CN113735980A (zh) * | 2021-08-23 | 2021-12-03 | 中国医学科学院北京协和医院 | 一种自融合串联蛋白修饰方法及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| EP0657175B1 (en) * | 1993-12-09 | 2005-03-02 | Centro de Inmunologia Molecular | Vaccine comprising human autologous epidermal growth factor and use thereof |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| JPH10147952A (ja) | 1996-11-18 | 1998-06-02 | Komatsu Ltd | ブルドーザのドージング装置 |
| JP5220248B2 (ja) | 1997-08-29 | 2013-06-26 | アンチジェニックス・インコーポレイテッド | アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物 |
| KR20010015817A (ko) * | 1997-11-14 | 2001-02-26 | 유로-셀티큐 에스.에이. | 항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체 |
| US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| CA2370697C (en) | 1999-04-19 | 2012-03-06 | Smithkline Beecham Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| US7078486B2 (en) * | 1999-12-10 | 2006-07-18 | Spectral Diagnostics, Inc. | Single-chain polypeptides comprising troponin I and troponin C |
| EP1268803A2 (en) * | 2000-03-23 | 2003-01-02 | Greenville Hospital System | Bi-functional cancer treatment agents |
| CU22999A1 (es) | 2001-12-04 | 2004-10-12 | Centro Inmunologia Molecular | Método de tratamiento de enfermedades malignas e infecciosas crónicas |
| US20050130886A1 (en) * | 2001-05-14 | 2005-06-16 | Jan Holmgren | Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| JP4298498B2 (ja) * | 2001-06-13 | 2009-07-22 | ゲンマブ エー／エス | 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体 |
| US6833441B2 (en) * | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| WO2003015705A2 (en) | 2001-08-17 | 2003-02-27 | Roger Williams Hospital | In situ immunization |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| CN1665931A (zh) * | 2002-05-31 | 2005-09-07 | 西根控股有限公司 | 从膜转运序列衍生的自身聚集或自身团聚嵌合蛋白 |
| AU2003900481A0 (en) * | 2003-02-05 | 2003-02-20 | Queensland University Of Technology | Synthetic modulators of cell migration and growth |
| US8207314B2 (en) * | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
| US7601341B2 (en) * | 2003-06-05 | 2009-10-13 | Research Development Foundation | Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis |
| JP4623625B2 (ja) | 2003-07-24 | 2011-02-02 | 株式会社AMBiS | ヘテロ型５量体組換えワクチン |
| US7320795B2 (en) * | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| US7754850B2 (en) * | 2005-02-11 | 2010-07-13 | University Of Southern California | Chimeric disintegrin domain |
| FR2882654B1 (fr) * | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| CN1686562A (zh) * | 2005-03-31 | 2005-10-26 | 南京大学 | 一种转铁蛋白与生物还原剂的结合物及其制备方法 |
| MX2008009970A (es) * | 2006-02-01 | 2008-11-19 | Univ Johns Hopkins | Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos. |
| DE602006015421D1 (de) * | 2006-04-13 | 2010-08-26 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | HER-2/neu Multipeptidimpfstoff |
| PL2041177T3 (pl) | 2006-06-02 | 2012-09-28 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| EP2044246A4 (en) * | 2006-07-06 | 2009-12-16 | Molecular Logix Inc | LIGAND DRUG DISCOVERY SYSTEM DOMINANT NEGATIVE |
| AU2007292221B2 (en) * | 2006-09-06 | 2013-08-29 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| CN1995064A (zh) * | 2006-12-20 | 2007-07-11 | 李欣越 | 增强生物活性的长效重组人红细胞生长因子融合蛋白及方法 |
| WO2008097817A2 (en) * | 2007-02-02 | 2008-08-14 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
| KR20090114430A (ko) * | 2007-02-02 | 2009-11-03 | 베일러 리서치 인스티튜트 | 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| JP2011187653A (ja) | 2010-03-08 | 2011-09-22 | Olympus Corp | 防水機器 |
| US9562109B2 (en) | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| WO2013076580A2 (en) * | 2011-11-23 | 2013-05-30 | Bioven 3 Limited | Recombinant proteins and their therapeutic uses |
-
2012
- 2012-11-21 WO PCT/IB2012/002876 patent/WO2013076580A2/en not_active Ceased
- 2012-11-21 PL PL12824705T patent/PL2782598T3/pl unknown
- 2012-11-21 KR KR1020197027075A patent/KR102274211B1/ko active Active
- 2012-11-21 ES ES12824705T patent/ES2812564T3/es active Active
- 2012-11-21 MY MYPI2018000286A patent/MY188083A/en unknown
- 2012-11-21 CA CA2856255A patent/CA2856255C/en active Active
- 2012-11-21 EP EP12824705.3A patent/EP2782598B1/en active Active
- 2012-11-21 MX MX2014006232A patent/MX354902B/es active IP Right Grant
- 2012-11-21 DK DK12824705.3T patent/DK2782598T3/da active
- 2012-11-21 AU AU2012342117A patent/AU2012342117B2/en active Active
- 2012-11-21 SI SI201231830T patent/SI2782598T1/sl unknown
- 2012-11-21 HU HUE12824705A patent/HUE050438T2/hu unknown
- 2012-11-21 CN CN201810569766.XA patent/CN108864291A/zh active Pending
- 2012-11-21 LT LTEP12824705.3T patent/LT2782598T/lt unknown
- 2012-11-21 CN CN201810569310.3A patent/CN108864261A/zh active Pending
- 2012-11-21 MX MX2018003596A patent/MX381185B/es unknown
- 2012-11-21 US US13/813,844 patent/US9902760B2/en active Active
- 2012-11-21 RS RS20200986A patent/RS60782B1/sr unknown
- 2012-11-21 HR HRP20201282TT patent/HRP20201282T1/hr unknown
- 2012-11-21 RU RU2014124923A patent/RU2650574C2/ru active
- 2012-11-21 BR BR112014012460-4A patent/BR112014012460B1/pt active IP Right Grant
- 2012-11-21 PT PT128247053T patent/PT2782598T/pt unknown
- 2012-11-21 MY MYPI2014701320A patent/MY184576A/en unknown
- 2012-11-21 JP JP2014542952A patent/JP6121436B2/ja active Active
- 2012-11-21 EP EP20170470.7A patent/EP3744343A1/en not_active Withdrawn
- 2012-11-21 CN CN201280067891.1A patent/CN104066447A/zh active Pending
- 2012-11-21 KR KR1020147016995A patent/KR102024066B1/ko active Active
-
2014
- 2014-05-15 IL IL232645A patent/IL232645B/en active IP Right Grant
-
2016
- 2016-01-15 US US14/996,553 patent/US20160207972A1/en not_active Abandoned
-
2017
- 2017-03-29 JP JP2017064763A patent/JP6570081B2/ja not_active Expired - Fee Related
- 2017-11-16 US US15/814,723 patent/US11198716B2/en active Active
- 2017-11-30 AU AU2017268634A patent/AU2017268634B2/en not_active Ceased
-
2018
- 2018-03-09 RU RU2018108421A patent/RU2766595C2/ru active
-
2019
- 2019-04-04 JP JP2019072235A patent/JP6953467B2/ja active Active
-
2020
- 2020-02-21 AU AU2020201297A patent/AU2020201297B2/en not_active Ceased
- 2020-12-22 IL IL279676A patent/IL279676A/en unknown
-
2021
- 2021-09-29 JP JP2021159307A patent/JP7470669B2/ja active Active
- 2021-11-08 US US17/521,121 patent/US12030920B2/en active Active
-
2024
- 2024-07-02 US US18/761,743 patent/US20250066439A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534258A5 (enExample) | ||
| HRP20201282T1 (hr) | Rekombinantni proteini i njihove terapeutske upotrebe | |
| Koirala et al. | Vaccines for COVID-19: The current state of play | |
| JP2013107899A5 (enExample) | ||
| RU2015143217A (ru) | Самособирающиеся синтетические белки | |
| HRP20100228T1 (hr) | Modificirani hekson protein adenovirusa i njegove uporabe | |
| HRP20200007T1 (hr) | Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba | |
| FI4206216T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi | |
| WO2012159006A3 (en) | Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof | |
| CA3138064A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| HRP20230065T1 (hr) | Humanizirana protutijela koja prepoznaju alfa-sinuklein | |
| RU2014143830A (ru) | Мультивалентные рекомбинантные вирусы птичьего герпеса и вакцины для иммунизации птиц | |
| JP2012511545A5 (enExample) | ||
| JP2016517402A5 (enExample) | ||
| BR112012028326A2 (pt) | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos | |
| MX2014004214A (es) | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2010521147A5 (enExample) | ||
| BR112013003361A2 (pt) | anticorpo, polinucleotídeo e polipeptídeo isolado, composição, vetor, célual hospedeira, método de produção de um anticorpo, conjugado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos de tratamento, de indução e de diagnóstico de doença em um indivíduo | |
| BR112012008946A2 (pt) | sequência polinucletídica isolada , molécula pollinucleotídica de rna, vetor ou plasmídeo , célula hospedeira , vírus a ser expresso , vacina , polipetídeo e composição de vacina | |
| RU2016112951A (ru) | Рекомбинанатные вирусы болезни марека и их применение | |
| JP2014510519A5 (enExample) | ||
| BRPI0816134A2 (pt) | Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. | |
| TW202202169A (zh) | 預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法 | |
| JP2016518379A5 (enExample) |